title: Evaluation of the micronucleus assay in bone marrow and peripheral blood of rats for the determination of cigarette mainstream-smoke activity.
abstract: The mammalian in vivo micronucleus assay is widely used as part of the genotoxicity testing battery required during the development of new drugs. As such, the in vivo micronucleus assay has been used in a battery of assays for the assessment of cigarette ingredients or design modifications to help ensure that there is no increase in risk or any new risk introduced by these additions or modifications. The present series of studies was conducted to optimize and evaluate this assay for the assessment of the effects of mainstream smoke on the micronucleus frequency in the bone marrow and peripheral blood of rats. In a first experiment, the optimal conditions for performing the micronucleus assay in these tissues were determined. This was done by use of two compounds known for their micronucleus-inducing activity, i.e., the clastogen cyclophosphamide and the aneugen colchicine. In a second experiment, the effects of tube restraint on untreated control rats were investigated. In a third experiment, the optimal conditions were used to assess the clastogenic/aneugenic activity of cigarette smoke in Sprague-Dawley rats. The rat micronucleus assay in both bone marrow and peripheral blood is able to detect clastogenic and aneugenic activity. The flow cytometric determination of micronucleated cells in rat blood is at least as sensitive as determinations in bone marrow. No statistically significant differences were observed in micronucleus frequencies between rats with and without the additional stress of tube restraint; however, the cautious approach would be to use a fresh-air-exposed group (with tube restraint) as the negative control in inhalation experiments. Using the conditions identified as optimal in the above-mentioned experiments, the micronucleus assay was not able to detect effects induced by smoke from conventional cigarettes. Nevertheless, the micronucleus assay will remain a valuable tool as part of a testing battery used to investigate possible adverse effects related to product modifications.
authors.affiliation: Philip Morris Research Laboratories bvba, Leuven, Belgium. Erikvan.Miert@pmintl.com
authors.forename: Erik
authors.initials: E
authors.lastname: Van Miert
authors.forename: Patrick
authors.initials: P
authors.lastname: Vanscheeuwijck
authors.forename: Kris
authors.initials: K
authors.lastname: Meurrens
authors.forename: Willy
authors.initials: W
authors.lastname: Gomm
authors.forename: Piter M
authors.initials: PM
authors.lastname: Terpstra
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000648:ultrastructure; D003078:Colchicine / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D008297:Male; D015162:Micronucleus Tests / Q000379:methods*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012156:Reticulocytes / Q000648:ultrastructure; D012906:Smoke / Q000009:adverse effects*; D014026:Nicotiana; D014028:Tobacco Smoke Pollution / Q000009:adverse effects*
chemical_list: D012906:Smoke; D014028:Tobacco Smoke Pollution; D003520:Cyclophosphamide; D003078:Colchicine